Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines

Critical Reviews in Immunology

Volumn 21, Issue 1-3, 2001, Pages 157-178

  Czerniecki, Brian J ^a   Cohen, Peter A ^b   Faries, Mark ^a   Xu, Shuwen ^a   Roros, James G ^a   Bedrosian, Isabelle ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CD4+ T cells; CD8+ T cells; Chemokines; Dc1; Dc2; Dendritic cells; IL 12; Interferon ; Tumor rejection

Indexed keywords

CANCER VACCINE; CD83 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 39; HLA ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROSTAGLANDIN E2;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONFERENCE PAPER; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD; CANCER VACCINES; CELL DIFFERENTIATION; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MONOCYTES; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS;

EID: 0034798364     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (94)

1. Dendritic cells and the control of immunity
2. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
3. Tolerance, danger and the extended family
4. Abundant empty class II MHC molecules on the surface of immature dendritic cells
5. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
6. Developmental regulation of MHC class II transport ion mouse dendritic cells
7. Maturation, activation, and protection of dendritic cells induced by double stranded RNA
8. Efficient presentation of soluble antigen by cultured human dendritic dells is maintained by granuloctye/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
9. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells
10. Reciprocal control of T helper cell and dendritic cell differentiation
11. H2, and nonpolarized cells
12. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
13. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal
14. H2 priming
15. 2, promote type 2 cytokine production in maturing human naive T helper cells
16. H2 cells
17. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
18. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
19. Regression of human metastatic renal cell carcinoma after vaccination with cell-dendritic cell hybrids
20. Dendritic cell based immunotherapy of prostate cancer
21. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
22. Tumor vaccine strategies that employ dendritic cells and tumor lysates: Experimental and clinical studies
23. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
24. Dendritic cells can present antigen in vivo in a toleregenic or immunogenic fashion
25. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10
26. The effect of calcineurin inhibitors and corticosteriods on the differentiation of human dendritic cells
27. Role of T cell subsets in tumor immunity
28. + T cell subpopulations in established pulmonary metastases
29. + T cells in tumor rejection; past evidence and current prospects
30. Gene-modified tumor vaccine with therapeutic potential shifts tumor specific T cell response from a type 2 to a type 1 cytokine profile
31. + peripheral blood monocytes
32. Dendritic cells: From ontogenetic orphans to myelomonocytic descendents
33. Proliferating dendritic cell progenitors in human blood
34. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4
35. Down-regulation and release of CD14 on human monocytes by IL-4 depends on the presence of serum or GM-CSF
36. + dendritic cells
37. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking
38. Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways
39. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily
40. Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA
41. Calcium ionophore treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells
42. + hematopoietic progenitors to dendritic cells: Evidence for protein kinase C-mediated signaling
43. + dendritic cells: The levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation
44. Selective suppression of interleukin-12 induction after macrophage receptor ligation
45. Receptor-activated calcium influx in human monocytes exposed to monocyte chemotactic protein-1 and related cytokines
46. SHIP modulates immune receptor responses by regulating membrane association of Btk
47. Structure, function and biology of SHIP proteins
48. Phosphatidylinositol-3,4,5-triphosphate/Tec kinase-dependent calcium signaling pathway: A target for SHIP-mediated inhibitory signals
49. Calcium signalling induces the acquisition of dendritic cell characteristics in CML myeloid progenitor cells
50. Calcium ionophore treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status or sensitivity to biologic agents
51. H cells
52. H1-inducing capacity in myeloid dendritic cells requires environmental instruction
53. High-level IL-12 production by human dendritic cells requires two signals
54. High level IL-12 production by murine dendritic cells: Upregulation via MHC Class II and CD40 molecules and downregulation by IL-4 and IL-10
55. H2s
56. T-cell subsets: Chemokine receptors guide the way
57. H2 cytokines IL-4 and IL-13
58. H2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine
59. Distinct patterns and kinetics of chemokine production regulate dendritic cell function
60. Divergent effects of interleukin-4 and interferon-γ on macrophage-derived chemokine production: An amplification circuit of polarized T helper 2 responses
61. Monocyte chemotactic protein 1 regulates oral tolerance induction by inhibition of T helper cell 1-related cytokines
62. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
63. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70
64. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of her-2/neu transgenic mice
65. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine IL-12
66. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu protooncogene in vitro
67. IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo
68. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
69. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
70. Enhanced expression of cyclooxgenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression
71. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: A general role for inflammation?
72. Enhanced growth of murine melanoma in ultraviolet-irradiated skin is associated with local inhibition of immune effector mechanisms
73. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
74. Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10
75. Interleukin 10 production by human melanoma
76. + T-cell subset inhibits antigen-specific T cell responses and prevents colitis
77. H2 T cells
78. + tumor-infiltrating lymphocytes
79. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2- T cells. Tumor eradication does not require participation of cytotoxic T cells
80. + T cell clones specific for the human p97 melanoma associated antigen can eradicate pulmonary metastases from a murine tumor expressing p97 antigen
81. + T cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens
82. Dissection of the lymphokine-activated killer phenomenon, Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis
83. Macrophages and metastasis - A biological approach to cancer therapy
84. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
85. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor draining lymph node cells
86. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2
87. Purification of L-selectin (low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
88. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein Barr virus-transformed B cells
89. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer
90. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
91. MAGE-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells
92. + hematopoietic progenitor cells
93. Immunization with a peptide epitope (369-377) from Her-2/neu leads to peptide specific cytotoxic T lymphocytes that fail to recognize Her-2/neu+ tumors
94. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant